Netherlands: The use of proton pump inhibitors (PPI) among kidney transplant recipients may lead to severe fatigue, fatigue severity, and lower mental and physical health-related quality of life, a new study has suggested. The study was published online in the American Journal Of Kidney Diseases.
Proton pump inhibitors (PPIs) are commonly prescribed medications for the management of acid-related gastrointestinal disorders.
Tim J. Knobbe and colleagues aimed to investigate the potential association between PPI use and fatigue as well as health-related quality of life among 937 kidney transplant recipients. Participants were at least one-year post-transplantation and were enrolled in the TransplantLines Biobank and Cohort Study.
Comments are closed.